The 2019 STAT Summit is a full-day, one-track program that will dive into the groundbreaking advances and emerging challenges that are shaping the future of health and medicine. Panel discussions and featured talks will cover everything that’s happening from the lab bench to the pharmacy counter, including the emerging role of artificial intelligence in drug development and novel ideas for how America can pay for costly new medicines.

We’ll continue to add sessions as they are finalized. Check in for updates, and please note that sessions are subject to change.

WEDNESDAY, NOV 20

5:00 p.m.
Registration

6:00 p.m.
Opening Remarks & Sponsor Welcome
STAT
Steven J. Ubl, President and CEO, PhRMA

Programming

7:00 p.m.
Cocktail Reception
Introduction by Philip Jones, Ph.D., Vice President, Therapeutics Discovery, Head of Drug Discovery, The University of Texas MD Anderson Cancer Center

THURSDAY, NOV 21

7:00 a.m.
Breakfast & Registration

8:00 a.m.
Opening Remarks & Sponsor Welcome
Linda Henry, Managing Director, STAT
Steven J. Ubl, President and CEO, PhRMA

Morning Sessions

12:00 p.m.
Lunch & Sponsor Keynote

1:30 p.m.
Afternoon Sessions

5:30 p.m.
Sponsor Farewell & Closing Remarks
Matthew Herper, Editorial Director, Events & Senior Writer, Medicine, STAT
Ramona Sequeira, M.B.A., President, United States Business Unit, Takeda

Cocktail Reception

SESSIONS

The gene therapy pioneers
Katherine High, M.D., President and Head of Research and Development, Spark Therapeutics 
For decades, gene therapy was a field in the wilderness, considered too risky to try and unlikely to be effective. Now, it is bringing a rush of potential cures. Hear from the scientists who made it happen.

What ‘breakthrough’ means to patients
David Fajgenbaum, M.D., M.B.A., M.Sc., Co-Founder & Executive Director, Castleman Disease Collaborative Network
Janet Freeman-Daily, Lung Cancer Patient/ Activist, GrayConnections.net
Matthew Might, Ph.D., Director, Hugh Kaul Precision Medicine Institute, University of Alabama at Birmingham
The people on this panel all have a deadly disease. But in each case, they’ve decided to fight it in every way they can. Here is what they have learned.

The Hypebusters
Otis Brawley, M.D., Bloomberg Distinguished Professor of Oncology and Epidemiology, Johns Hopkins University
Steve Nissen, M.D., M.A.C.C., Chief Academic Officer for the Heart and Vascular Institute, Cleveland Clinic
With breakthroughs come hype. So we’ve assembled a crew who has had a role in spotting unsafe medicines, ineffective treatments, and outright fraud. They’ll tell us what to watch out for.

SPONSOR SPOTLIGHT
Gianluca Pirozzi, M.D., Ph.D., Head of Development for Rare Diseases and Translational Gene Therapy, Sanofi 

Introducing the 2019 STAT Wunderkinds
Introduction by Jason Bock, Ph.D., Vice President, Therapeutics Discovery, Head of Biologics Product Development, The University of Texas MD Anderson Cancer Center

Each year STAT selects a new class of Wunderkinds, to celebrate the next generation of scientific superstars who are actively shaping the future of medicine. Come meet this year’s winners.

SPONSOR KEYNOTE
Arie Belldegrun, M.D., F.A.C.S., Executive Chairman and Co-Founder, Allogene Therapeutics

Nurturing innovation
Laurie Glimcher, M.D., President and CEO, Dana-Farber Cancer Institute
Lloyd Minor, M.D., Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine
It’s tough to pay for your innovation as an academic medical center. Two top administrators and the chief executive of an insurer talk about what’s changing in medicine and where the next breakthroughs will come from.

Can AI fix drug R&D?
Daphne Koller, Ph.D., Founder and CEO, Insitro
Aviv Regev, HHMI Investigator, professor of biology at MIT, and Core Institute Member and Chair of the Faculty, Broad Institute of MIT and Harvard
Hal Barron, M.D., Chief Scientific Officer and President, R&D, GlaxoSmithKline
Artificial intelligence has seen a lot of hype in drug development, but the reality lags behind. Some say that’s changing. Hear from some believers, and learn what might go wrong.

SPONSOR SESSION
A conversation with Amgen
Patrick Dey, Vice President Digital Health & Innovation, Amgen

STAT Biomedical Innovation Award
Presented by Dr. Morris Birnbaum, SVP, Chief Scientific Officer, Pfizer
STAT, with the help of a panel of experts, will recognize a top researcher in biology or medicine whose work has helped to define their field, helping patients.

Building the new Bristol-Myers Squibb
Giovanni Caforio, M.D., Chairman and CEO, Bristol-Myers Squibb
Moderator: Matthew Herper, Editorial Director, Events & Senior Writer, Medicine, STAT
With its purchase of Celgene, the drug giant that created the cancer immunotherapy market is executing one of the biggest mergers in years. What will it mean for research?

SPONSOR SESSION
A conversation with Alkermes
Mark Namchuk, Ph.D., SVP Research, Pharmaceutical and Non-clinical Development, Alkermes

Building on a breakthrough
Jeffrey Leiden, M.D., Ph.D., CEO, Vertex Pharmaceuticals
Moderator: Matthew Herper, Editorial Director, Events & Senior Writer, Medicine, STAT
Vertex Pharmaceuticals has developed therapies that are having a big impact on cystic fibrosis. Can the company have a similar impact on other rare diseases?

The state of biotech
Jacqualyn Fouse, Ph.D., CEO, Agios Pharmaceuticals 
We live in an age of miracles, but they come at a high cost – literally, with new gene therapies costing millions of dollars each. Can we afford them?